<DOC>
	<DOC>NCT00872300</DOC>
	<brief_summary>The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.</brief_summary>
	<brief_title>PHA-739358 for the Treatment of Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>active multiple myeloma progressing after at least 2 prior lines of treatment measurable disease t(4;14) translocation life expectancy of at least 3 months uncontrolled hypertension myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months. pregnancy or breast feeding active infections, including HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>